VRTX Q1 2022 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.1B+21.6% YoY

Gross Profit

$1.9B88.3% margin

Operating Income

$1.0B49.6% margin

Net Income

$762M36.3% margin

EPS (Diluted)

$2.96

QoQ Revenue Growth

+1.2%

Cash Flow

Operating Cash Flow

$956M

Free Cash Flow

$893M

Stock-Based Comp.

$130M

Balance Sheet

Total Assets

$14.3B

Total Liabilities

$3.3B

Stockholders' Equity

$10.9B

Cash & Equivalents

$7.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.1B	$1.7B	+21.6%
Gross Profit	$1.9B	$1.5B	+20.9%
Operating Income	$1.0B	$888M	+17.2%
Net Income	$762M	$653M	+16.7%

Revenue Segments

TRIKAFTA/KAFTRIO

$1.8B84%

KALYDECO

$139M7%

ORKAMBI

$132M6%

SYMDEKO/SYMKEVI

$65M3%

Geographic Segments

UNITED STATES

$1.4B65%

Europe

$632M30%

Other, Non U.S.

$97M5%